Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > BUSINESS
BUSINESS
- ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
- Ex-Otsuka Kagaku Exec Becomes PeptiStar’s New President
June 24, 2019
- Lantus/Lyxumia Combo Shows Effectiveness in Japan PIII: Sanofi
June 21, 2019
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Japan IBD Market Projected at 155.8 Billion Yen in 2027: Fuji Keizai
June 20, 2019
- Fujifilm to Invest 300 Million Yen in Shimane Univ. Spinoff Regenerative Medicine Biotech
June 20, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
- Eisai, Harvard Researchers Develop Novel Anticancer Agent Derived from Total Synthesis of Halichondrin
June 19, 2019
- Keytruda Momentum Unabated at ASCO, Snapshot of 5 Checkpoint Inhibitors
June 18, 2019
- 281 Apply for Torii’s Voluntary Redundancy Program
June 18, 2019
- Cold Agglutinin Disease Patients Have High Thromboembolism Event Risk: Sanofi Database Study
June 18, 2019
- VC Catalys Pacific Kicks Off in Japan in Partnership with Chugai, Eisai, Takeda, and More
June 18, 2019
- Daiichi Sankyo Espha Rolls Out AstraZeneca’s 3 Cancer AGs; Gx Onslaught for Lonasen, Urief
June 14, 2019
- Sumitomo Dainippon Tweaks Healios Cell Therapy Deal, Now Leads Japan Trials
June 14, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Shionogi Snaps Up Osaka Biotech after Hitting Joint Study Goals
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Growth of Japan Pharma Business Counts on Partnership with Foreign Biotechs: IQVIA Director
June 13, 2019
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…